Agency for Medicinal Products and Medical Devices of the Republic of Slovenia

Biologicals/biosimilar approved in EU and marketed in SI

Biosimilars approved in the EU published at EMA website – LINK

By clicking on an individual drug, the following information is displayed: overview about the drug in English and Slovenian, authorization details in English, Summary of the main characteristics of the drug – SmPC – in Slovenian and English, Assessment history (EPAR) in English.

Information on the current status of the drug’s presence on the Slovenian market is available on the website of the central drug database: Central drug database 2 – Search (cbz.si)

(Last update: March 2026)

Adalimumab

Refence:

Biosimilars:

Aflibercept

Reference:

Biosimilars:

Others:

Bevacizumab

Reference:

Biosimilars:

Denosumab

Reference:

Biosimilars:

Reference:

Biosimilars:

Ekulizumab

Reference:

Biosimilar:

Enoxaparin sodium

Reference:

Clexane

Biosimilars:

Epoetein

Reference:

Biosimilars:

Others:

Eporatio (epoetin theta)

NeoRecormon (epoetin beta)

Etanercept

Reference:

Biosimilars:

Filgrastim

Reference:

Biosimilars:

Follitropine alfa

Reference:

Biosimilars:

Puregon (follitropin beta)

Rekovelle (follitropin delta)

Golimumab

Reference:

Biosimilars:

Infliximab

Reference

Biosimilars:

Insulin Asparte

Reference:

Biosimilars:

Insulin Degludek

Insulin Degludec/liraglutide

Insulin Degludec/Insulin aspart

Insulin Detemir

Insuline Glargine

Reference:

Biosimilars:

Others:

Suliqua (insulin glargine + lixisenatide)

Insulin Human

Humulin M3

Humulin N

Humulin R

Insulin glulisine

Natalizumab

Omalizumab

Reference:

Biosimilars:

Pegfilgrastim

Reference:

Biosimilars:

Ranibizumab

Reference:

Biosimilar:

Rituximab

Reference:

Biosimilars:

Somatropine

Reference:

Biosimilars:

Others:

Teriparatide

Reference:

Biosimilars:

Tocilizumab

Reference:

Biosimilar:

Tocilizumab STADA (Tofidence)

Trastuzumab

Reference:

Biosimilars:

Others:

Enhertu (trastuzumab deruxtecan)

Kadcyla (trastuzumab emtansine)

Phesgo (trastuzumab + pertuzumab)

Ustekinumab

Reference:

Biosimilar:

Details

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.

Necessary

Always Enabled

Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.

Cookie	Duration	Description
cookielawinfo-checkbox-necessary	1 year	Set by the GDPR Cookie Consent plugin, this cookie is used to record the user consent for the cookies in the "Necessary" category
CookieLawInfoConsent	1 year	Records the default button state of the corresponding category & the status of CCPA. It works only in coordination with the primary cookie

Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.

Cookie	Duration	Description
pll_language	1 year	The pll _language cookie is used by Polylang to remember the language selected by the user when returning to the website, and also to get the language information when not available in another way.